Gossamer Bio, Inc. (GOSS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Rigel Pharmaceuticals, Inc.

Gossamer Bio, Inc.

Astria Therapeutics, Inc.

Omeros Corp.

Merrimack Pharmaceuticals, Inc.

Acrivon Therapeutics, Inc.

PolyPid Ltd.

Allakos, Inc.

Lyra Therapeutics, Inc.

Regencell Bioscience Holdings Ltd.

Eagle Pharmaceuticals, Inc.

Why is Gossamer Bio, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of 110.41% and Operating profit at 5.31% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -13.48

With a fall in Net Sales of -88.01%, the company declared Very Negative results in Jun 25

The company has declared negative results in Jan 70 after 8 consecutive negative quarters
NET SALES(Q) At USD 11.49 MM has Fallen at -88.01%
OPERATING PROFIT(Q) Lowest at USD -38.55 MM
PRE-TAX PROFIT(Q) Lowest at USD -38.27 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 367.68%, its profits have risen by 68.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Gossamer Bio, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Gossamer Bio, Inc.

374.29%

5.81

92.02%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

110.41%

EBIT Growth (5y)

5.31%

EBIT to Interest (avg)

-13.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

9.49

Sales to Capital Employed (avg)

0.43

Tax Ratio

1.77%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-48.57

EV to EBIT

-4.46

EV to EBITDA

-4.76

EV to Capital Employed

-3.72

EV to Sales

1.96

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0.83% (YoY

-33What is not working for the Company

NET SALES(Q)

At USD 11.49 MM has Fallen at -88.01%

OPERATING PROFIT(Q)

Lowest at USD -38.55 MM

PRE-TAX PROFIT(Q)

Lowest at USD -38.27 MM

NET PROFIT(Q)

Lowest at USD -38.27 MM

DEBT-EQUITY RATIO (HY)

Highest at 21.87 %

EPS(Q)

Lowest at USD -0.17

Here's what is working for Gossamer Bio, Inc.

Raw Material Cost

Fallen by 0.83% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Gossamer Bio, Inc.

Net Sales

At USD 11.49 MM has Fallen at -88.01%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -38.27 MM has Fallen at -171.32%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -38.27 MM has Fallen at -177.74%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Profit

Lowest at USD -38.55 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -38.27 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -38.27 MM and Fallen

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

EPS

Lowest at USD -0.17

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Highest at 21.87 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio